Previous
Previous

Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in HR-NBL Patients

Next
Next

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with HR-NBL (HR-NBL1/SIOPEN ph 3 trial)